Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | DSIP (Delta Sleep-Inducing Peptide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | 30-60 minutes before desired sleep onset. Evening only. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 2-4 week cycles with equal rest periods to prevent tolerance. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit brain hypothalamus in 1977. It modulates GABAergic neurotransmission by potentiating GABA-activated currents in hippocampal and cerebellar neurons while blocking NMDA-activated potentiation in cortical neurons. It also interacts with opioid-associated receptors, modulates serotonin and dopamine systems (increasing serotonin levels), and promotes delta wave (slow-wave) sleep through mechanisms that remain incompletely characterized.
Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal.
30-60 minutes before desired sleep onset. Evening only.
2-4 week cycles with equal rest periods to prevent tolerance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →